Medical research

Nusinersen (Spinraza)

Read the nusinersen Q&A


On 21st April, the Committee for Medicinal Products for Human Use (CHMP) announced that it has recommended Biogen be granted a license for nusinersen as a treatment for SMA. Spinraza is the brand name for the drug, nusinersen. This approval is for a broad licence, meaning that Spinraza will used for children and adults with SMA types 1-3.

The European Commission will now review the CHMP’s recommendation. This process will take about 3 months. If and when the European Commission grants Biogen a license, it will be up to the National Institute for Health and Care Excellence (NICE), NHS England, the Scottish Medicines Consortium and other authorities in the devolved nations to decide whether to fund the drug in England, Scotland, Wales and Northern Ireland. This would usually be in line with the terms of the licence set out by the European Commission.

NICE has already started what is called a ‘scoping’ process, which means it is gathering evidence about SMA and nusinersen, to help decide whether to review the drug should the EMA grant Biogen a licence. An initial meeting to consider this will take place this month. The SMA Trust and representatives from Muscular Dystrophy UK and SMA Support UK will be there. Together, we will be advocating for a review that will consider broad approval for all types of SMA. If a review does go ahead there will then be an opportunity for families to have their say.

Read the CHMP Press Release

For more information:

The SMA Trust will continue to work with MD UK, SMA Support UK, NICE, clinicians and Biogen in order to move things forward. We will keep you informed of progress via our website, email and social media.

We will continue to do all we can to move the process forward, keep you updated and ensure that your voices are heard.